Mass Spectrometry–Based Phosphoproteomic Markers to Predict Kinase Inhibitor Response in Solid Tumors
Mass spectrometry-based phosphoproteomics has emerged as a powerful tool for predicting kinase inhibitor responses in solid tumors, offering direct functional insights into signaling pathways that surpass traditional genomic profiling by capturing dynamic kinase activities and adaptive resistance mechanisms.
Mass spectrometry, BRAF/MEK inhibitors, clinical translation, EGFR inhibitors, kinase inhibitors, liquid biopsy, machine learning, multiomic integration, phosphoproteomic biomarkers, phosphoproteomics, precision oncology, predictive biomarkers, resistance mechanisms, signaltransduction pathways, solid tumors.